from VALBIOTIS (EPA:ALVAL)
VALBIOTIS : Oral presentation at the 2024 EASD congress
VALBIOTIS SA
Valbiotis
La Rochelle, September 5, 2024 (5:40 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French scientific research laboratory specializing in the development and marketing of dietary supplements for preventing and combating metabolic disorders causing cardiovascular disease, announces that it has been selected to present clinical results from the TOTUM•63 Phase II/III clinical study in prediabetes and type 2 diabetes at the 2024 European Association for the Study of Diabetes (EASD) congress.
Full results from the Phase II/III REVERSE-IT clinical study were published on September 11, 2023 (press release) and had demonstrated an impressive efficacy of TOTUM•63 against prediabetes and the early stages of the type 2 diabetes. These results have been already presented at the American Diabetes Association’s 84th Scientific sessions (press release).
In the field of early glycemic disorders, the REVERSE-IT clinical study constitutes a world first for a non-drug active substance, both in terms of its scale (636 volunteers) and the number of centers involved internationally (52 centers in 7 countries).
About Valbiotis Valbiotis is a French scientific research laboratory specializing in the development and marketing of dietary supplements for preventing and combating metabolic disorders causing cardiovascular disease. Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce metabolic disorders and cardiovascular risk factors, relying on a multi-target strategy enabled by the use of plant-based resources. In France, Valbiotis is responsible for its own sales and marketing. Internationally, Valbiotis' products are the subject of licensing agreements. Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company. For more information about Valbiotis, please visit: www.valbiotis.com Contacts Corporate Communication / Valbiotis +33 5 46 28 62 58
Financial Communication / Seitosei-Actifin Marianne PY +33 1 80 48 25 31 marianne.py@seitosei-actifin.com
Media Relations / Agence Monet +33 1 45 63 12 43
Regulatory filing PDF file File: 2024-09-05-PRVALBIOTISEASDT63 |
Language: | English |
Company: | VALBIOTIS SA |
12F, Rue Paul Vatine | |
17180 Périgny | |
France | |
Phone: | 0546286258 |
E-mail: | contact@valbiotis.com |
Internet: | www.valbiotis.com |
ISIN: | FR0013254851 |
Euronext Ticker: | ALVAL |
AMF Category: | Inside information / Other releases |
EQS News ID: | 1980845 |
End of Announcement | EQS News Service |
1980845 05-Sep-2024 CET/CEST